Proactive Investors - Run By Investors For Investors

Redx Pharma Plc RNS Release

Redx presentations at AACR 2017

RNS Number : 3242Y
Redx Pharma plc
02 March 2017

2 March 2017



("Redx" or "the Company" or "the Group")


Redx to present new scientific data at AACR 2017


Redx, the drug development company, is pleased to announce that it will present two scientific posters at the American Association for Cancer Research (AACR) Annual Meeting April 1-5, 2017, in Washington D.C., USA.



Session Date & Time

April 5, 2017, 8:00 AM -12:00 PM Eastern Time

Session Title

Enzymes and Hormones and Metabolism in Tumor Immunity

Presentation Title

Development of 2nd generation indoleamine 2,3-dioxygenase 1 (IDO1) selective inhibitors

Session Location

Section 24

Abstract #

5581 / 13

First author

Thomas Pesnot

Abstract online!/4292/presentation/6237



Session Date & Time

April 5, 2017, 8:00 AM -12:00 PM Eastern Time

Session Title

Oncogenes and Tumor Suppressors as Therapeutic Targets

Presentation Title

Development of REDX05358, a novel highly selective and potent pan RAF inhibitor and a potential therapeutic for BRAF and RAS tumors

Session Location

Section 6

Abstract #

5160 / 3

First author

Helen Mason

Abstract online!/4292/presentation/4116



Dr Neil Murray, CEO of Redx, said:


"We're delighted to present new scientific data on two of our pre-clinical programs at the AACR meeting in April. As we are moving closer to the clinic with our most advanced programs, the Porcupine inhibitor RXC004 and the reversible BTK inhibitor RXC005, we continue to look for novel opportunities in several therapeutic classes in oncology and immunology.'



For further information, please contact:


Redx Pharma Plc

Neil Murray, Chief Executive

T: +44 151 706 4747

Karl Hård, Head of Investor Relations &

Corporate Communications

T: +44 7491 651 406


Cantor Fitzgerald Europe (Nomad & Broker)


T: +44 20 7894 7000

Phil Davies/ Michael Reynolds


About Redx Pharma Plc

Company website:


Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, infection and immunology, providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a broad portfolio of proprietary drug programs.




This information is provided by RNS
The company news service from the London Stock Exchange

Redx Pharma Plc Timeline

CN Research
April 06 2017

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use